Holen Sie sich die Stockscreener-App
4.10
2.15%
-0.09
Ernexa Therapeutics Inc Aktie (ERNA) Neueste Nachrichten
Enterprise value to EBIT forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to revenue forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Should I Buy ERNA? ERNA 2026 AnalysisIntellectia AI™ - intellectia.ai
Director takes 2026 cash pay in options at Ernexa (ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) director granted options in place of cash fees - Stock Titan
Ernexa Therapeutics (ERNA) grants director 5,944-share option - Stock Titan
Ernexa Therapeutics Inc. (ERNA) grants CEO 118,848 options expiring 2036 - Stock Titan
Ernexa (NASDAQ: ERNA) pays director with $4.57 stock options - Stock Titan
Eterna Therapeutics Inc (NASDAQ: ERNA) Share Price, ERNA Stock News, ERNA Share Price & Updates - Kalkine
Ernexa Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Ernexa (NASDAQ: ERNA) director’s warrant set to lapse after Phase 1 data - Stock Titan
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - Yahoo Finance
Ernexa (ERNA) Earnings Reading: Reported EPS Misses Expectations at the Close; Closing Move: The Market Price Advances 3.60%Free Cash Flow Trends - vinanet.vn
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayEBITDA Analysis - vinanet.vn
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - qz.com
Ernexa Therapeutics Warrants (ERNAW) Hold at $0.05 as Price Action Remains FlatAccumulation Line - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackCatalyst Driven Stocks - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Regression Channel - vinanet.vn
Ernexa Therapeutics Warrants (ERNAW) Surge 20% to $0.06 as Speculative Interest BuildsFibonacci Extension - vinanet.vn
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com Nigeria
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Strengthens Board with Veteran Biotech - GlobeNewswire
Biotech veteran with 25 years’ experience joins Ernexa board - Stock Titan
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Warrants (ERNAW) Hold Flat at $0.04 as Support and Resistance AlignCall Resistance - vinanet.vn
Ernexa Therapeutics (ERNA) Drops Nearly 5% as Bearish Pressure Builds Near Key SupportMarket Profile - dars.gov.et
Ernexa Therapeutics Inc. Revenue Breakdown – BOATS:ERNAW - TradingView
Ernexa Therapeutics Warrants (ERNAW) Slide 21.79% as Penny-Stock Volatility IntensifiesVolatility Surface - vinanet.vn
Ernexa Therapeutics Inc. (ERNA) stock price, news, quote and history - Yahoo Finance UK
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa Therapeutics advances ERNA-101, a cell t... - Pluang
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 - GlobeNewswire
Tumors cleared in about two-thirds of animals in ERNA-101 study - Stock Titan
Ernexa Therapeutics (ERNA) Q3 2023 Earnings: Clinical-Stage Biotech Reports Wider Loss as Pipeline Advances - dars.gov.et
Ernexa's Innovative Approach to Cancer Treatment - intellectia.ai
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.07 as Trading Lacks DirectionAnalyst Upgrade Stocks - vinanet.vn
ERNA Q3 2023 Earnings: Loss Per Share Deepens, Stock Slides 16.39%Annual Earnings Summary - Vinanet
Ernexa Therapeutics Warrants (ERNAW) Hold Steady at $0.07: Minimal Price Action in Thin TradingRSI Overbought Alerts - vinanet.vn
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy - Sahm
3 Most Active Penny Stocks to Watch Today, 7/16/2026 - TipRanks
ERNA Stock Whipsaws As Ernexa Maps Path To First Human Trial - StocksToTrade
ERNA stock jumps as investors appear to refocus on ERNA-101 clinical milestones - Quiver Quantitative
ERNA Stock Pops As Ernexa Flags Progress Toward First Trials - StocksToTrade
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Yahoo Finance
ERNA Stock Draws Trader Attention As Biotech Maps 2026–2027 Trial Roadmap - timothysykes.com
Wednesday's pre-market session: top gainers and losers - ChartMill
Ernexa's ERNA-101 combo clears tumors and boosts survival in ovarian cancer preclinical study. - Pluang
Ernexa reports positive preclinical data for cancer therapy By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ernexa Therapeutics Reports Independent Preclinical Validation of ERNA-101 Combination Therapy Ahead of Planned IND Submission - Quiver Quantitative
Ernexa Therapeutics stock surges 30% on preclinical data By Investing.com - Investing.com Canada
Ernexa Therapeutics Receives Independent Validation of - GlobeNewswire
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):